XML 23 R7.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF CASH FLOWS
¥ in Thousands, $ in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
CNY (¥)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
CNY (¥)
Dec. 31, 2022
CNY (¥)
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss ¥ (652,075) $ (89,333) ¥ (531,021) ¥ (768,990)
Adjustments to reconcile net loss to net cash generated from operating activities:        
Share-based compensation (note 24)     0 (5,919)
Depreciation of property, plant and equipment (note 10) 84,775 11,614 82,124 88,692
Amortization of intangible assets (note 13) 36,355 4,981 36,705 34,495
Amortization of land lease payments (note 11) 9,627 1,319 9,625 9,627
Lease expense to reduce operating lease ROU 22,578 3,093 26,683 19,322
Income from equity method investments (12,696) (1,739) (20,789) (17,647)
Change in fair value of derivative liability (note 22) (166) (23) (5,207) (1,015)
Changes in fair value of short-term investments (7,290) (999) 0 0
(Gain) loss on disposal of long-lived assets 13,110 1,796 (62) 3
Deferred tax expense (benefit) (15,652) (2,144) (13,039) (71,848)
Allowance for doubtful accounts, net 128,196 17,563 64,712 5,400
Interest and consultation expenses 193,199 26,468 165,669 120,357
(Gain) Loss on disposal of subsidiaries (note 4) (48,497) (6,644) 638 61,546
Gain on sale of partial interests in an equity method investment 120 16 (37,498) 0
Loss from agreements termination with a cooperative hospital     0 204,250
Changes in operating assets and liabilities net of effects of acquisition and disposals:        
Accounts receivable 12,018 1,646 36,454 644
Prepayments and other current assets (335,657) (45,986) (149,738) (130,156)
Inventories 6,498 890 44,489 (46,750)
Other non-current assets (458) (63) 1,618 (15)
Accounts payable 93,052 12,748 15,779 113,743
Accrued expenses and other liabilities 97,497 13,357 70,838 119,055
Deferred revenue (3,089) (423) (41,179) 57,168
Income tax payable 101 14 705 818
Accrued unrecognized tax benefit 35 5 (15,830) (6,539)
Operating lease liabilities (19,330) (2,647) (18,147) (2,935)
Net cash used in operating activities (397,749) (54,491) (276,471) (216,694)
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of land use right     0 (215)
Investment in equity method investees     0 (2,300)
Investment in equity investments without readily determinable fair value     (100) 0
Acquisitions of business, net of cash acquired     0 0
Acquisitions of property, plant and equipment (150,772) (20,656) (113,003) (222,980)
Acquisitions of intangible assets (10,160) (1,392) (4,211) (818)
Deposits for the purchases of property, plant and equipment (249,902) (34,235) (2,699) (160,793)
Proceeds from disposal of property, plant and equipment     310 5,635
Proceed from agreements termination with a cooperative hospital     0 238,093
Proceeds from principal portion of direct financing leases     0 7,536
Proceeds from disposal of subsidiaries 9,057 1,241 0 0
Cash distribution from equity method investments 10,000 1,370 12,022 5,101
Proceeds from disposal of certain percentage of an equity method investment     60,000 0
Investment in a joint venture (102,000) (13,974) 0 0
Proceeds from disposal of other investment 27,664 3,790 0 0
Purchase of short - term investment (204,607) (28,031) 0 0
Proceeds from disposal of short - term investment 77,276 10,587 0 0
Redemption of available-for-sale debt securities     0 11,949
Net cash used in investing activities (593,444) (81,300) (47,681) (118,792)
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from short-term bank borrowings 504,699 69,143 337,695 217,470
Proceeds from long-term bank and other borrowings 1,917,174 262,652 110,000 422,765
Borrowings from related parties (note 26) 300,543 41,174 22,150 220,369
Repayment to related parties (note 26) (335,359) (45,944) (61,777) (82,915)
Repayment of short-term bank and other borrowings (360,329) (49,365) (442,858) (197,598)
Repayment of long-term bank and other borrowings (1,391,219) (190,596) (7,561) (197,003)
Purchase of subsidiary shares from noncontrolling interests     0 0
Capital injection from a noncontrolling interests in a subsidiary   0 300,004 0
Proceeds from initial public offering of Concord Healthcare Group Co., Ltd. 510,522 69,941   0
Net cash generated from financing activities 1,146,031 157,005 257,653 383,088
Effect of foreign exchange rate changes on cash and cash equivalent and restricted cash (8,275) (1,134) (2,425) (47,170)
Net increase (decrease) in cash 146,563 20,080 (68,924) 432
Cash and cash equivalents and restricted cash at beginning of the year 90,419 12,387 159,343 158,911
Cash and cash equivalents and restricted cash at end of the year 236,982 32,467 90,419 159,343
Reconciliation of cash and cash equivalents and restricted cash to the consolidated balance sheets:        
Cash and cash equivalents 216,224 29,623 58,139 158,283
Restricted cash, current portion 20,758 2,844 32,280 1,060
Restricted cash, noncurrent portion       0
Total cash and cash equivalents and restricted cash 236,982   90,419 159,343
Supplemental schedule of major cash flows information:        
Income tax paid (148) (20) (898) (3,013)
Interest paid (188,304) (25,798) (152,359) (145,257)
Supplemental schedule of major non-cash activities:        
Acquisition of property, plant and equipment, construction in progress and other intangible assets through utilization of deposits 79,644 10,911 5,812 257,440
Offset of Loan from a related party and Loan to a related party ¥ 34,307 $ 4,700   0
Acquisition of property, plant and equipment, construction in progress and other intangible assets included in accrued expense and other liabilities     ¥ 285,358 ¥ 2,181